
On January 11, 2022, the FDA updated the Johnson & Johnson/Janssen COVID-19 Vaccine Fact Sheet for Health Care Providers Administrating with information regarding the serious risk of Immune Thrombocytopenia (ITP)...

On July 13, 2021, the FDA announced revisions to the Fact Sheet for Healthcare Providers administering the Janssen/Johnson & Johnson COVID-19 vaccine and the Fact Sheet for Recipients and Caregivers...

On April 13, 2021, the FDA and CDC paused use of the vaccine after serious blood clots were reported in women between the ages of 18 and 49. By April...

On June 1, 2023, the FDA revoked the EUA for Johnson & Johnson/Janssen COVID-19 vaccine. According to the FDA, Janssen BioTech had requested the voluntary withdrawal of its COVID-19 vaccine...

Long-term follow-up of clinical trial participants to monitor for conditions such as cancer and autoimmune diseases will become difficult, if not impossible. In December 2020, Pfizer-BioNTech officials stated that they...

Health officials have cautioned that symptoms of adverse reactions following COVID-19 vaccination may overlap with those of COVID-19 illness and be difficult to distinguish. However, symptoms of loss of taste...

According to the federal vaccine adverse event reporting system (VAERS), as of CDC’s December 27, 2024 release of data there were a total of 565,373 reports submitted to VAERS associated...

In June 2022, the FDA authorized use of a 25mcg Moderna COVID-19 mRNA vaccine in infants and children ages six months through five years, to be given as a 2-dose...

In June 2022, the FDA authorized use of two doses of a 100mcg Moderna COVID-19 mRNA vaccine in adolescents 12 through 17 years of age and two doses of a...

Moderna COVID-19 Vaccine Trial Data in AdultsOn May 18, 2020, Moderna, Inc. of Cambridge, Massachusetts announced that it had obtained “positive interim clinical data” from a Phase 1 human clinical...